Volume : 12, Issue : 10, October – 2025
Title:
A CRITICAL REVIEW OF PAEDIATRIC DRUG SAFETY,REGULATORY OVERSIGHT AND PUBLIC HEALTH RESPONSE IN INDIA 2025
Authors :
Kartik D. Chavhan*, Shivshankar G. Devkunbi, Dr. Swati P. Deshmukh
Abstract :
A number of children died and were hospitalized as a result of upsetting public health concerns regarding pediatric cough syrups in India in 2025. These occurrences brought to light significant pharmacovigilance procedures and regulatory shortcomings. They also underscored the urgent need for reform to enhance medication safety in India, with a particular focus on pediatric formulations. In order to improve medication regulation, manufacturing monitoring, and public health policy in India, this review provides the available data, regulatory reactions, toxicological findings, and lessons learned. This article’s goals are to give a general overview of pediatric pharmacovigilance, illustrate its differences from adult pharmacovigilance, and offer real-world instances. The Food and Drug Administration in the US has a reputable division dedicated to overseeing the development of pharmaceuticals for children. Similarly, the Central Drugs Standard Control Organization (CDSCO) in India has the authority to impose rules tailored to the production of pediatric medications. There is an urgent need to address the problem and introduce particular drug development guidelines in order to control and safeguard the interests of the pediatric population in light of the planned revisions to India’s drug development guidelines.
Cite This Article:
Please cite this article in press Kartik Devidas Chavhan et al., A critical review of paediatric drug safety,Regulatory oversight and public health response in india 2025, Indo Am. J. P. Sci, 2025; 12(10).
REFERENCES:
1. Jasso-Gutiérrez L, Castellanos-Solís EC, Santos-Preciado JI. The importance of pharmacovigilance in the pediatric population. Bol Med Hosp Infant Mex. 2009;66(3):221–228.
2. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Medical Dictionary for Regulatory Activities (MedDRA)—MedDRA® Term Selection: Points to Consider. Endorsed Guide for MedDRA Users Release 4.19 based on MedDRA Version 23.0. 1 Mar 2020. Available from:
admin.new.meddra.org/sites/default/files/guidance/file/000401_termselptc_r4_19_mar 2020_13.pdf [Accessed 2020 Sep 30].
3. The Times of India. 11 children dead after consuming Coldrif cough syrup in Madhya Pradesh. 2025. Available from: timesofindia.indiatimes.com
4. The Times of India. WHO issues medical product alert on four cough syrups made by India’s Maiden Pharmaceuticals [Internet]. 2022. Available from:
timesofindia.indiatimes.com/india/who-issues-medical-product-alert-on-four-cough-s yrups-made-by-indias-maiden-pharmaceuticals/articleshow/94665994.cms
5. Council for International Organizations of Medical Sciences (CIOMS). Practical aspects of signal detection in pharmacovigilance: Report of CIOMS Working Group
VIII. Geneva: CIOMS; 2010. Available from: cioms.ch/working_groups/working-group-viii/ [Accessed 2020 Aug 28].
6. European Medicines Agency (EMA). Guidelines on Good Pharmacovigilance Practices (GVP)—Introductory cover note, last updated with Chapter P.III on pharmacovigilance for the use of medicines by pregnant and breastfeeding women.
2019. Available from:
www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidelinesgood-p harmacovigilance-practices-gvp-introductory-cover-note-lastupdated-chapter-piii_en. pdf [Accessed 2020 Aug 17].
7. European Medicines Agency (EMA). Guideline on Good Pharmacovigilance Practices (GVP): Product- or population-specific considerations IV—Paediatric population. 2018. Available from:
www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigil ancepractices-gvp-product-population-specific-considerations-iv_en0.pdf [Accessed 2020 Aug 17].
8. European Medicines Agency (EMA). Guidance on the format of the risk management plan (RMP) in the EU—in integrated format, EMA/164014/2018 Rev.2.0.1 accompanying GVP Module V Rev.2, Human Medicines Evaluation. Published 2018
Oct 31. Available from:
www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-formatriskmanagement-plan-rmp-eu-integrated-format-rev201_en.pdf [Accessed 2020 Aug 17].
9. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). ICH harmonised guideline—Integrated addendum to ICH E6(R1): Guidelines for good clinical practice E6(R2). Current Step
4 version dated 2016 Nov 9. Available from: database.ich.org/sites/default/files/E6_R2_Addendum.pdf [Accessed 2020 Nov 14].
10. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). ICH harmonised guideline—Addendum to
ICH E11: Clinical investigation of medicinal products in the pediatric population
E11(R1), final version. Adopted 2017 Aug 18. Available from: database.ich.org/sites/default/files/E11_R1_Addendum.pdf [Accessed 2010 Nov 14].
11. Mankar SD, Gholap VD, Zende TP, Dighe RS. Drug regulatory agencies in India, USA, Europe and Japan—a review. Int J Inst Pharm Life Sci. 2014;4(2):288–297.
12. Central Drugs Standard Control Organization (CDSCO). Homepage. Available from: www.cdscoonline.gov.in/CDSCO/homepage [Accessed 2025 Oct 24].
13. Anusha T, Nagabhushanam MV. Role of regulatory affairs for new drug approval procedure in India. Int J Pharm Anal Res. 2017;6(2):431–441.
14. The Gazette of India. New Drugs and Clinical Trial Rules, 2019. Available from: www.iscr.org [Accessed 2025 Oct 24].
15. Sharma P, Gupta S. Regulatory gaps in India’s pharmaceutical industry: a review. Indian J Pharmacol. 2023;55(2):98–104.
16. BBC News. WHO warning: contaminated cough syrup linked to child deaths in India
[Internet]. 2025. Available from: https://www.bbc.com/news/articles/c3vzgz794wro 17. Deutsche Welle (DW). India’s cough syrup tragedy shows huge drug safety gaps
[Internet]. 2025. Available from: www.dw.com/en/indias-cough-syrup-tragedy-shows-huge-drug-safety-gaps/a-743528
62
18. CNN. WHO warning over contaminated cough syrup linked to India deaths [Internet].
2025.
Available from:
www.cnn.com/2025/10/14/world/who-warning-contaminated-cough-syrup-india-deat hs-intl-hnk
19. Vision IAS. Cough syrup deaths in India: understanding the contamination crisis and regulatory response [Internet]. 2025. Available from:
www.visionias.in/blog/current-affairs/cough-syrup-deaths-in-india-understanding-thecontamination-crisis-and-regulatory-response
20. BBC News. WHO raises alarm over new cases of toxic cough syrup contamination [Internet]. 2025. Available from: https://www.bbc.com/news/articles/ceq28jey1xwo 21. World Health Organization (WHO). Medical product alert No. 5/2025: Substandard (contaminated) oral liquid medicines [Internet]. 2025 Oct 13. Available from: www.who.int/news/item/13-10-2025-medical-product-alert-n-5-2025–substandard-(c ontaminated)-oral-liquid-medicines
22. Reuters. WHO issues alert over contaminated cough syrups in India [Internet]. 2025.
Available from:
www.reuters.com/business/healthcare-pharmaceuticals/who-issues-alert-over-contami nated-cough-syrups-india-2025-10-13/
23. Reuters. India to force drugmakers to upgrade plants after fatal cough syrup crisis
[Internet]. 2025. Available from:
www.reuters.com/business/healthcare-pharmaceuticals/india-force-drugmakers-upgra de-plants-after-fatal-cough-syrup-crisis-2025-10-17/
24. ScanX Trade. India tightens regulations on cough syrup manufacturing following child deaths [Internet]. 2025. Available from:
scanx.trade/stock-market-news/stocks/india-tightens-regulations-on-cough-syrup-man ufacturing-following-child-deaths/22830083
25. Study IQ. Drug safety issues in Indian pharmaceutical sector [Internet]. 2025.
Available from: www.studyiq.com/articles/drug-safety-issues-in-indian-pharmaceutical-sector/
26. Medstown. How drug abuse among children is driving India’s pharmacy surveillance and trade policies in 2025 [Internet]. 2025. Available from: www.medstown.com/how-drug-abuse-among-children-is-driving-indias-pharmacy-su rveillance-and-trade-policies-in-2025/
27. Health Policy Watch. Toxic cough syrup, weak oversight: India’s unending drug safety crisis [Internet]. 2025. Available from:
healthpolicy-watch.news/toxic-cough-syrup-weak-oversight-indias-unending-drug-saf ety-crisis/
28. PubMed Central (PMC). Article reference: PMC12351480 [Internet]. Available from: pmc.ncbi.nlm.nih.gov/articles/PMC12351480/
29. International Journal of Contemporary Pediatrics. Downloadable article on pediatric safety [Internet]. Available from:
www.ijpediatrics.com/index.php/ijcp/article/download/6624/4060/30840
30. Press Information Bureau (PIB). Press release PRID 2175135 [Internet]. 2025.
Available from: www.pib.gov.in/PressReleasePage.aspx?PRID=2175135
31. World Health Organization (WHO). WHO launches global accelerator for paediatric formulations: strategic roadmap 2025–2030 [Internet]. 2025 May 20. Available from: www.who.int/news/item/20-05-2025-who-launches-global-accelerator-for-paediatric-f ormulations-strategic-roadmap-2025-2030
32. The Wire. WHO flags persisting regulatory gaps that put Indians at risk from toxic cough syrups [Internet]. 2025. Available from:
m.thewire.in/article/health/who-flags-persisting-regulatory-gaps-that-put-indians-at-ri sk-from-toxic-cough-syrups
33. PW Only IAS. Drug safety concerns in India [Internet]. 2025. Available from: pwonlyias.com/current-affairs/drug-safety-concerns-in-india/
34. US Embassy India. Health alert: recall of specific children’s cough and cold medicines in India [Internet]. 2025. Available from:
in.usembassy.gov/health-alert-recall-of-specific-childrens-cough-and-cold-medicinesin-india/
35. World Health Organization (WHO). WHO publications catalogue item: B09475
[Internet]. Available from: www.who.int/publications/i/item/B09475